| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Harish Shantharam is Chief Financial Officer at ALXO. Harish Shantharam's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $97K at current prices.
Net of sales, the ALXO filings show accumulation of 75,000 shares.
Harish Shantharam has 5 Form 4 filings on record from January 2025 to January 2026, all as Chief Financial Officer at Alx Oncology (ALXO), 2025–2026.
The 5 reported transactions were 4 option or other derivative awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $58K and no sales.
The only open-market purchase was 75,000 shares of ALXO at an average $0.78 on August 18, 2025, about $58K. Twelve months later ALXO was up 114%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 18, 2025 | ALXO Alx Oncology Holdings Inc | Chief Financial Officer | Buy | 75,000 | $0.78 | $58,402.50 | New | +60.7% | +114.2% |